AbbVie Maps Post-HUMIRA Growth With Apogee Deal, Immunology Pipeline

AbbVie executives outlined a growth strategy focused on expanding its pipeline and business-development activity across immunology, neuroscience, oncology and obesity. The company aims to diversify beyond its established SKYRIZI and RINVOQ franchises, signaling a constructive long-term outlook but providing no new financial targets or near-term earnings metrics.